Pfizer has announced its intention to acquire the biotech firm Metsera for $4.9 billion, a strategic move aimed at bolstering its portfolio in the competitive obesity treatment sector. The deal, which values Metsera at $47.50 per share—a 43% premium over its recent closing price—also includes a contingent value right that could add up to $22.50 per share depending on the achievement of clinical and regulatory milestones.
This acquisition comes as Pfizer faces challenges in developing new obesity therapies, a market that has seen increased interest and investment in recent years. Founded in 2022, Metsera has quickly gained traction, having secured $290 million in initial funding and going public earlier this year. The integration of Metsera’s innovative pipeline could provide Pfizer with a significant advantage in addressing the growing demand for effective weight loss solutions.
Start your 7-day trial and see what the database can do →
